Unravelling the Adiponectin Hallmark and Exploring the Therapeutic Potential of Its Receptor Agonists in Cancer Metabolic Reprogramming
Biomolecules · 2025
DOI: 10.3390/biom15060820 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, 2025. Verfasst von Sanober Kafeel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy. Hauptthemen laut MEDLINE: Neoplasms, Receptors, Adiponectin, Adiponectin, Piperidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Campania "L. Vanvitelli", University of Campania “Luigi Vanvitelli”, iRESCUE project.
Abstract (Originalsprache)
As the most abundant fat-derived hormone, adiponectin plays an essential role in regulating energy homeostasis. Current evidence proposes the serum levels of adiponectin as a risk factor and a diagnostic/prognostic biomarker in cancer. Moreover, distinctive antineoplastic features have also been reported as a result of adiponectin supplementation in preclinical models. Mapping of the cancer-associated metabolic changes has elucidated a highly adaptable and interconnected system that allows malignant cells to sustain their growth and survival. Along with the pyruvate into acetyl-CoA conversion, downregulation of both lactate dehydrogenase and glycolysis-related genes depicts the main adiponectin-induced perturbations affecting glucose metabolism in cancer. Meanwhile, a multi-level approach involving lipid trafficking, catabolism, and de novo synthesis has been attributed to adiponectin in malignancies. The adiponectin receptor agonist AdipoRon has recently been recognized as a promising antineoplastic compound. Remarkably, AdipoRon-mediated changes in cancer metabolism occur together with its antiproliferative potential. This review aimed at recapitulating the modulatory effects of adiponectin, as well as those of its synthetic receptor agonists, in driving metabolic alterations in cancerous cells. A critical discussion is also conducted to deduce whether the adiponectin axis could serve as a putative target to address the metabolic reprogramming in cancer progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
- Department of Mechanistic Cell Biology, Max Plank Institute of Molecular Physiology, 44227 Dortmund, Germany.
ORCID-Profile: Sanober Kafeel, Luigi Sapio
Förderung
- University of Campania "L. Vanvitelli"
- University of Campania “Luigi Vanvitelli”, iRESCUE project
Zitieren
APA
Kafeel, S., Palmiero, G., Salzillo, A., Ragone, A., Naviglio, S., & Sapio, L. (2025). Unravelling the Adiponectin Hallmark and Exploring the Therapeutic Potential of Its Receptor Agonists in Cancer Metabolic Reprogramming. Biomolecules. https://doi.org/10.3390/biom15060820
Vancouver
Kafeel S, Palmiero G, Salzillo A, Ragone A, Naviglio S, Sapio L. Unravelling the Adiponectin Hallmark and Exploring the Therapeutic Potential of Its Receptor Agonists in Cancer Metabolic Reprogramming. Biomolecules. 2025. doi:10.3390/biom15060820
BibTeX
@article{Kafeel2025,
author = {Kafeel, Sanober and Palmiero, Giuseppina and Salzillo, Alessia and Ragone, Angela and Naviglio, Silvio and Sapio, Luigi},
title = {Unravelling the Adiponectin Hallmark and Exploring the Therapeutic Potential of Its Receptor Agonists in Cancer Metabolic Reprogramming},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15060820}
}
EUVIMED